HIV

More than 99% effective at preventing HIV in trials, Yeztugo (lenacapavir) is now the first and only twice-yearly option for pre-exposure prophylaxis (PrEP).

A new study found that implementing a specialty pharmacy program at St. Jude Children’s Research Hospital helped more young HIV patients achieve medication adherence and undetectable viral loads.

Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV infections.

Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

Medicaid is the main healthcare coverage for people living with HIV in the United States, according to data compiled by KFF.

In United States veterans, antiretroviral resistance was associated with higher healthcare resource utilization, despite lower pharmacy-related costs, according to an abstract submitted to the Academy of Managed Care Pharmacy (AMCP) held last week in Houston.

The Xpert MTB/Ultra molecular diagnostic test may become a viable option for detecting tuberculosis (TB) in the stool of adults with HIV, according to the results of a recent study.

The Centers for Disease Control and Prevention’s Division of HIV Prevention are a critical source of funding and outreach for states, according to Terri L. Wilder, MSW, HIV/Aging Policy Advocate at SAGE, an organization that serves LGBTQ+ elders.

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the potential for extended dosing intervals.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded those from the twice-yearly dosing.

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, according to new research published in Health Science Reports.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.

The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.

Positive HIV status as well as socioeconomic disadvantages, not breastfeeding, are associated with infant length and birth weight, according to the results of a new South African study.

PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.

Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

After several days of worry that the global AIDS program might come to abrupt end, Secretary of State Marco Rubio issued a humanitarian waiver that appears to have restored funding.

In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who weigh at least 13 pounds.

Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund, explains the biggest HIV issues anticipated this year.

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice yearly investigational pre-exposure prophylaxis (PrEP) injection.

Researchers are currently enrolling participants to test the effectiveness of a rectal douche containing the antiretroviral drug tenofovir in a study that is expected to finish in January 2026.

A new study found that iron supplements are safe for children with HIV in Uganda, as they improve hemoglobin levels without increasing malaria risk.

A recent study reveals that nearly 20% of United States physicians treating HIV patients plan to leave or reduce their caseload within five years, even as demand for HIV care is expected to rise.

A closer look at the available PrEP options available in the United States.

Early trial data of two virally suppressed, breast-feeding women with HIV shows that there may be less of a risk of HIV transmission during breastfeeding than previously believed.